China Tian Yuan Healthcare Group Limited (0557) AI Stock Analysis

China Tian Yuan Healthcare Group Limited

(HKEX:0557)

Select Model

Rating:44Neutral

Price Target:HKD 0.61▲(24.95% Upside)

Action:reiterated

Date:09/27/26

The score is weighed down primarily by weak financial performance—shrinking revenue and persistent operating/net losses—despite moderate leverage and improved recent cash flow. Technicals add pressure with the stock trading below major moving averages and a negative MACD (downtrend), even though the RSI suggests an extremely oversold condition. Valuation is constrained by negative earnings (negative P/E), offering limited support without a dividend yield.

Positive Factors

Moderate LeverageModerate leverage indicates the company is not heavily debt-funded, preserving financial flexibility relative to a more highly leveraged structure. This can reduce balance-sheet pressure and leave greater capacity to manage obligations while pursuing operational improvements.

Negative Factors

Revenue ContractionA sustained decline in revenue indicates weakening top-line momentum and reduces the scale available to absorb fixed operating costs. Unless growth recovers, the contraction can continue to limit investment capacity, competitive progress, and the prospect of achieving operating leverage.

China Tian Yuan Healthcare Group Limited (0557) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 197.50M
Dividend Yield: ―
Average Volume (3M): 25.50K
Price to Earnings (P/E): -7.0
Beta (1Y): -1.30
Revenue Growth: 50.78%
EPS Growth: 15.62%
Country: Hong Kong
Employees: 33
Sector: Financial
Sector Strength: 68
Industry: Medical - Distribution

China Tian Yuan Healthcare Group Limited Business Overview & Revenue Model

Company Description

China Tian Yuan Healthcare Group Limited, an investment holding company, provides healthcare related services in Hong Kong, the People's Republic of China, and Korea. It operates through Investment Holding, Healthcare, Money Lending and Related Busin...

China Tian Yuan Healthcare Group Limited Financial Statement Overview

Summary

Financial results are pressured: revenue has contracted sharply in recent years and the company remains consistently unprofitable (negative EBIT/EBITDA and sizable net losses). Offsetting this somewhat, leverage looks moderate (debt-to-equity ~0.20–0.24) and operating/free cash flow has been positive in 2023–2025, but earnings quality remains a key risk.

Income Statement

24Negative

Balance Sheet

58Neutral

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	30.79M	19.18M	26.84M	45.23M	54.22M	94.59M
Gross Profit	16.38M	9.59M	14.91M	25.16M	31.52M	71.31M
EBITDA	1.65M	-3.51M	-27.22M	-15.79M	-13.08M	-2.89M
Net Income	-26.75M	-34.01M	-34.24M	-15.48M	-29.04M	-16.85M
Balance Sheet
Total Assets	242.65M	224.98M	260.93M	302.95M	333.55M	376.40M
Cash, Cash Equivalents and Short-Term Investments	42.63M	29.51M	27.05M	26.73M	31.60M	77.89M
Total Debt	37.46M	38.72M	40.77M	45.91M	51.13M	59.66M
Total Liabilities	88.39M	88.36M	84.98M	87.77M	91.52M	92.35M
Stockholders Equity	164.09M	161.22M	194.68M	230.26M	224.30M	256.25M
Cash Flow
Free Cash Flow	8.58M	9.12M	10.67M	4.51M	-31.71M	14.86M
Operating Cash Flow	10.36M	9.41M	10.69M	5.10M	-30.36M	16.32M
Investing Cash Flow	10.76M	-292.00K	-3,000	364.00K	-1.23M	-1.42M
Financing Cash Flow	-5.15M	-5.05M	-10.85M	-8.77M	-12.49M	-7.22M

China Tian Yuan Healthcare Group Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price0.48

Price Trends

50DMA0.52Negative

100DMA0.56Negative

200DMA0.56Negative

Market Momentum

MACD-0.00Positive

RSI41.79Neutral

STOCH76.19Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0557, the sentiment is Negative. The current price of 0.48 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.52, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.79 is Neutral, neither overbought nor oversold. The STOCH value of 76.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0557.

China Tian Yuan Healthcare Group Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (68)

Financial Indicators

HK:0557 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:1221	72Outperform	HKD 1.70B	17.30	2.28%	2.11%	3.53%	-7.42%
HK:0184	68Neutral	HKD 768.85M	2.54	8.45%	5.53%	6.80%	67.22%
Sector *	68Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
HK:1270	67Neutral	HKD 1.54B	4.46	3.55%	7.36%	5.13%	585.92%
HK:0201	62Neutral	HKD 608.40M	16.19	0.90%	―	6.29%	―
HK:0557	44Neutral	HKD 193.51M	-6.98	-16.34%	―	50.78%	15.62%
HK:0078	38Underperform	HKD 337.04M	-0.69	-6.04%	―	49.29%	79.61%

* Financial Sector Average

Performance Comparison

HK:0557 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:0557	China Tian Yuan Healthcare Group Limited	0.48	-0.34	-41.57%
HK:0184	Keck Seng Investments (Hong Kong)	2.26	0.12	5.56%
HK:1270	Langham Hospitality Investments	0.43	-0.04	-7.64%
HK:0201	Magnificent Hotel Investments Limited	0.07	-0.00	-2.86%
HK:1221	Sino Hotels (Holdings) Ltd.	1.42	0.01	0.57%
HK:0078	Regal Hotels International Holdings Limited	0.38	-0.22	-37.50%

China Tian Yuan Healthcare Group Limited Corporate Events

China Tian Yuan Healthcare Swings to Interim Profit on Surging Revenue

Aug 28, 2026

China Tian Yuan Healthcare Group Limited reported a sharp improvement in its interim performance for the six months ended 30 June 2026, with revenue climbing to HK$20.0 million from HK$8.4 million a year earlier. The group swung to an unaudited conso...

China Tian Yuan Healthcare Schedules Board Meeting on Interim Results and Dividend

Aug 14, 2026

China Tian Yuan Healthcare Group Limited is a Cayman Islands-incorporated healthcare group listed in Hong Kong and focused on medical and healthcare services. Its board consists of an executive director, a non-executive director and three independent...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 27, 2026

China Tian Yuan Healthcare Group Limited AI Stock Analysis